These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. Pradere B; D'Andrea D; Schuettfort VM; Foerster B; Quhal F; Mori K; Abufaraj M; Margulis V; Deuker M; Briganti A; Muilwijk T; Hendricksen K; Lotan Y; Karakiewic P; F Shariat S; World J Urol; 2021 Jul; 39(7):2567-2577. PubMed ID: 33067726 [TBL] [Abstract][Full Text] [Related]
16. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study. Hamaya T; Hatakeyama S; Tanaka T; Kubota Y; Togashi K; Hosogoe S; Fujita N; Kusaka A; Tokui N; Okamoto T; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Ohyama C BJU Int; 2021 Oct; 128(4):468-476. PubMed ID: 33484231 [TBL] [Abstract][Full Text] [Related]
17. High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. Meng X; Chao B; Vijay V; Silver H; Margolin EJ; Balar A; Taneja SS; Shah O; Bjurlin MA; Anderson CB; Huang WC Urology; 2019 Jul; 129():146-152. PubMed ID: 30930207 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. Necchi A; Lo Vullo S; Mariani L; Moschini M; Hendricksen K; Rink M; Sosnowski R; Dobruch J; Raman JD; Wood CG; Margulis V; Roupret M; Briganti A; Montorsi F; Xylinas E; Shariat SF; BJU Int; 2018 Feb; 121(2):252-259. PubMed ID: 28940605 [TBL] [Abstract][Full Text] [Related]